More recently, BLU-285, a new investigational agent, has shown highly potent and selective targeting ofKIT/PDGFRA GIST mutants and high activity against imatinib-resistant GIST patient-derived xenografts of aKIT exon 11/17 mutant and aKIT exon 11/13 mutant68. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.